Litcius/Paper detail

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Ying Cheng, Yun Fan, Yanqiu Zhao, Dingzhi Huang, Xingya Li, Peng Zhang, Mafei Kang, Nong Yang, Diansheng Zhong, Zhen Wang, Yan Yu, Yu Zhang, Jun Zhao, Tai Qin, Chenqi Chen, Shiangjiin Leaw, Wenjuan Zheng, Yong Song

2024Journal of Thoracic Oncology133 citationsDOIOpen Access PDF

Topics & Concepts

MedicineHazard ratioInternal medicinePlaceboInterquartile rangeEtoposideClinical endpointCarboplatinChemotherapyRandomized controlled trialConfidence intervalSurgeryGastroenterologyCisplatinPathologyAlternative medicineLung Cancer Research StudiesPARP inhibition in cancer therapyNeutropenia and Cancer Infections